Market Overview

Amerivision International, Inc. Settles Suit and Paves the Way for Future Growth


BLOOMINGTON, Minn., Aug. 28, 2018 (GLOBE NEWSWIRE) -- AmeriVision International, Inc., today announced it has settled its lawsuit with Nova Oculus. The parties have agreed to drop all claims against each other and to cease any future litigation.

According to Marshall Masko, vice chair of Amerivision, the terms of the settlement are confidential and under a court ordered non-disclosure order. Amerivision COO Blair Mowery further stated that the companies have no business relationship with each other and will not going forward.

Amerivision is a U.S. software and medical device company with technology designed to restore and improve vision among patients afflicted with age-related macular degeneration, or atrophic macular degeneration (AMD), a common blinding disease associated with an aging population. Amerivision's innovative, new technology focuses on restoring or improving vision to patients who have lost sight due to the "dry" form of this devastating visual disease.

"The dry form of macular degeneration is a huge unaddressed medical need," Mr. Masko said. "Over one quarter of people aged 65+ have AMD. The National Institute of Health (NIH) estimates 10 Million Americans and 16 million Europeans suffer from macular degeneration. Among the Americans with the condition, 90 percent have the dry or atrophic form, where blood vessels to the retina atrophy, cutting off the blood supply to the rod and cone cells responsible for the visual process."

Currently, there is no approved treatment to restore lost vision from this disease, according to the Mayo Clinic's June 2018 Newsletter. "We believe Amerivision has a very important calling, in helping to restore patients' lost vision," said Masko.

Amerivision is a privately held company, driven by technology and clinical research. The Company has stated that it intends to enter the European marketplace to begin treating patients, prior to expansion in other markets.

Contact Info:
Stacy Einck
(952) 224-2939, x13

Primary Logo

View Comments and Join the Discussion!